select trial semaglutide nejm Trial: 2.4 mg Cuts Cardiovascular Risk in Obesity (NEJM 2023) Semaglutide in Patients with Obesity-Related

Gross hematuria is less common but more likely to indicate an underlying condition that needs evaluation

3C, E and F)

Your Patient Journey: Complete Medical Intake: Secure, HIPAA-compliant online questionnaire

Understanding vascular ultrasound results needs a healthcare providers help

In the SURPASS-2 head-to-head trial (Fras et al., NEJM 2021), tirzepatide 15mg reduced body weight 5.5kg more than semaglutide 1mg over 40 weeks in a type 2 diabetes population

It helps researchers unpack core molecular events driving tumor initiation and progressive malignant development, meanwhile facilitating the screening and confirmation of prospective anti-tumor therapeutic targets